Browse Conditions Browse Medicines

NICE approve use of ertugliflozin (Steglatro▼) in treatment of type 2 diabetes

Steglatro▼, for Type 2 diabetes from Merck Sharp and Dohme

The National Institute for Health and Care Excellence (NICE) have approved the use of Merck Sharp & Dohme's type 2 diabetes treatment ertugliflozin, brand name Steglatro▼. This means the medicine can be prescribed in England and Wales.

The guidance states that 'ertugliflozin is available on the NHS. It is a possible treatment, with drugs called metformin and a DPP‑4 inhibitor, for type 2 diabetes in adults if:
  • your blood glucose levels can't be managed by diet and exercise alone
  • metformin and a DPP‑4 inhibitor are not controlling the diabetes, and
  • pioglitazone or a sulfonylurea are not right for you
The group of medicines called DPP-4 inhibitors include:
  • alogliptin - brand name Vipidia
  • alogliptin with metformin - brand name Vipdomet
  • linagliptin - brand name Trajenta
  • linagliptin with metformin - brand name Jentadueto
  • linagliptin with empagliflozin - brand name Glyxambi
  • saxagliptin - brand name Onglyza
  • saxagliptin with dapagliflozin - brand name Qtern
  • saxagliptin with metformin - brand name Komboglyze
  • sitagliptin - brand name Januvia
  • sitagliptin with metformin - brand name Janumet
  • vildagliptin - brand name Galvus
  • vildagliptin with metformin - brand name Eucreas

You can follow developments on Steglatro by using our Medicines Tracker service which provides users with updates about the medicines they are interested in.

About Steglatro (source EMA)
Steglatro is a medicine used to control blood glucose (sugar) levels in adults with type 2 diabetes together with diet and exercise.

Steglatro can be used in combination with other diabetes medicines or on its own in patients who cannot take metformin.

Type 2 diabetes is a disease in which the body does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. The result is a high level of glucose in the blood.

The active substance in Steglatro, ertugliflozin, helps to lower blood glucose by making the patient pass out glucose in the urine. It does this by blocking a protein in the kidneys (called SGLT2) that normally takes glucose back into the blood from the kidneys.

Steglatro was first made available in the EU in 2018. It is manufactured by Merck Sharp & Dohme.

European Medicines Agency website page for Steglatro
Accessed 06/06/19
Links available in full article

© NICE [2019] Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes. Technology appraisal guidance [TA583] Published date: 05 June 2019 Available from: See Link below. All rights reserved. Subject to Notice of rights
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

The information provided by NICE was accurate at the time this article was issued.

NICE information on Steglatro

New medicines and vaccines that are under additional monitoring have an inverted black triangle symbol (▼) displayed in their package leaflet and summary of product characteristics, together with a short sentence explaining what the triangle means – it does not mean the medicine is unsafe. You should report all suspected adverse drug reactions (ADRs) for these products. ADRs can be reported by your doctor, pharmacist or online via the Yellow Card system.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions (side effects) after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals or patients are asked to report any suspected adverse reactions via the Yellow Card Scheme at or search for MHRA Yellow Card in the Google Play or Apple App Store.

Disclaimer: This site is designed to offer information for general educational purposes only. The health information furnished on this site and the interactive responses are not intended to be professional advice and are not intended to replace personal consultation with a qualified physician, pharmacist, or other healthcare professional. We cannot provide individual medical advice. You must always seek the advice of a professional for questions related to a disease, disease symptoms, and appropriate therapeutic treatments.

About condition About medicine